Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options

Curr Opin Pharmacol. 2021 Oct:60:1-10. doi: 10.1016/j.coph.2021.06.003. Epub 2021 Jul 14.

Abstract

Maternal gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy, which can adversely affect the short- and long-term health of mothers and newborns. In recent years, several studies have revealed the early impact of maternal hyperglycemia on fetal growth trajectory and birth weight abnormalities in GDM-exposed pregnancies. However, an intense debate continues regarding the mode and optimal timing of diagnosis and treatment of this condition. The purpose of this review is to provide a brief overview of the understanding of GDM and its implications for fetal growth, addressing the modulatory role of medical nutrition therapy and available pharmacological antidiabetic agents (i.e. insulin, metformin, and glyburide), and to identify gaps in current knowledge toward which future research should be directed.

Keywords: Fetal growth; Gestational diabetes; Insulin therapy; Maternal hyperglycemia; Metformin.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diabetes, Gestational* / diagnosis
  • Diabetes, Gestational* / drug therapy
  • Female
  • Fetal Development*
  • Glyburide / therapeutic use
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Infant, Newborn
  • Insulin / therapeutic use
  • Metformin / therapeutic use
  • Pregnancy

Substances

  • Hypoglycemic Agents
  • Insulin
  • Metformin
  • Glyburide